AdvaMed Dx
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firms bioMerieux, Gen-Probe and Quidel recently joined AdvaMed's newly formed in-vitro-diagnostics-focused AdvaMed Dx division (1"The Gray Sheet" Dec. 21, 2009). Each of the companies had been in AdavMed at one time, but had let their memberships lapse
You may also be interested in...
AdvaMed Begets "AdvaMed Dx" For IVD-Focused Lobbying Effort
AdvaMed is forming an "association within an association" to focus exclusively on in vitro diagnostics, the group announced Dec. 17
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.